Immunostaining revealed strong cytoplasmic expression of CXCR7 in 74.5% (35/47), weak expression in 17% (8/47), and heterogeneous expression (weak and strong) in 8.5% (4/47) of the tumor samples (Figure 6c and Table 2). Here, ACKR3 is linked to neoplasm.